Muthu Vaduganathan (@mvaduganathan) 's Twitter Profile
Muthu Vaduganathan

@mvaduganathan

Cardiologist & Trialist @BrighamWomens @harvardmed | AE @JACCJournals | Podcast #DontMissABeat & #HFinFocus | Disclosures: bit.ly/3icLqlg

ID: 888976053951180801

linkhttps://connects.catalyst.harvard.edu/Profiles/display/Person/108817 calendar_today23-07-2017 04:16:22

6,6K Tweet

8,8K Takipçi

509 Takip Edilen

Muthu Vaduganathan (@mvaduganathan) 's Twitter Profile Photo
Muthu Vaduganathan
@mvaduganathan

21 days ago

Just 5 years ago, HFpEF was described as the “stepchild” of HF with no approved therapies. Today, there are 5 US FDA therapies: ✅ Empagliflozin (#EMPEROR) ✅ Dapagliflozin (#DELIVER) ✅ Sotagliflozin (#SOLOISTWHF) ✅ Sacubitril/Valsartan (#PARAGONHF) ✅ Finerenone (#FINEARTSHF)

Just 5 years ago, HFpEF was described as the “stepchild” of HF with no approved therapies. Today, there are 5 US FDA therapies: ✅ Empagliflozin (#EMPEROR) ✅ Dapagliflozin (#DELIVER) ✅ Sotagliflozin (#SOLOISTWHF) ✅ Sacubitril/Valsartan (#PARAGONHF) ✅ Finerenone (#FINEARTSHF)